Aurobindo Pharma Ltd updates on US FDA inspection at Unit 3

The United States Food and Drug Administration (US FDA) inspected the Company's Unit III, a Formulation manufacturing facility situated at Bachupally Village, Medchal Malkajgiri District, Telangana, from July 14 to July 21, 2023.

The Unit has now received an Establishment Inspection Report classifying the facility as "Voluntary Action Indicated" ("VAI").

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 861.10 as compared to the previous close of Rs. 862.95. The total number of shares traded during the day was 37225 in over 1278 trades.

The stock hit an intraday high of Rs. 868.30 and intraday low of 858.75. The net turnover during the day was Rs. 32170350.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 Unit3 USFDA Inspection EIR VAI